Please use this identifier to cite or link to this item: http://elea.unisa.it:8080/xmlui/handle/10556/1381
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSerio, Bianca-
dc.contributor.authorRisitano, Antonio M.-
dc.contributor.authorGiudice, Valentina-
dc.contributor.authorMontuori, Nunzia-
dc.contributor.authorSelleri, Carmine-
dc.date.accessioned2014-06-04T10:08:40Z-
dc.date.available2014-06-04T10:08:40Z-
dc.date.issued2014-
dc.identifier.citationSerio B, Risitano AM, Giudice V, Montuori N, Selleri C. Immunological derangement in Hypocellular Myelodysplastic Syndromes. Translational Medicine @ UniSa 2014;8(5):31-42en_US
dc.identifier.issn2239-9747en_US
dc.identifier.urihttp://hdl.handle.net/10556/1381-
dc.identifier.urihttp://dx.doi.org/10.14273/unisa-230-
dc.description.abstractHypocellular or hypoplastic myelodysplastic syndromes (HMDS) are a distinct subgroup accounting for 10–15% of all MDS patients, that are characterized by the presence of bone marrow (BM) hypocellularity, various degree of dysmyelopoiesis and sometimes abnormal karyotype. Laboratory and clinical evidence suggest that HMDS share several immune-mediated pathogenic mechanisms with acquired idiopathic aplastic anemia (AA). Different immune-mediated mechanisms have been documented in the damage of marrow hematopoietic progenitors occurring in HMDS; they include oligoclonal expansion of cytotoxic T lymphocytes (CTLs), polyclonal expansion of various subtypes of T helper lymphocytes, overexpression of FAS-L and of the TNF–related apoptosis-inducing ligand (TRAIL), underexpression of Flice-like inhibitory protein long isoform (FLIPL) in marrow cells as well as higher release of Th1 cytokines, such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). It has also been documented that some HMDS patients have higher frequency of polymorphisms linked both to high production of proinflammatory cytokines such as TNF-α and transforming growth factor-β and to the inhibition of T-cell mediated immune responses such as interleukin-10, further suggesting that immune-mediated mechanisms similar to those seen in AA patients may also operate in HMDS. Clinically, the strongest evidence for immune–mediated hematopoietic suppression in some HMDS is the response to immunosuppression including mainly cyclosporine, anti-thymocyte globulin and/or cyclosporine, or alemtuzumab. Here we review all these immune mechanisms as well as the influence of this deranged cellular and humoral immunologic mileau on the initiation and possible progression of MDS. All these observations are pivotal not only for a better understanding of MDS pathophysiology, but also for their immediate clinical implications, eventually leading to the identification of MDS patients who may benefit from immunosuppression.en_US
dc.format.extentP. 31-42en_US
dc.language.isoenen_US
dc.sourceUniSa. Sistema Bibliotecario di Ateneoen_US
dc.subjectHypoplastic myelodysplastic syndromeen_US
dc.subjectImmune systemen_US
dc.subjectBone marrow microenvironmenten_US
dc.titleImmunological derangement in Hypocellular Myelodysplastic Syndromesen_US
dc.typeArticleen_US
Appears in Collections:Translational Medicine @ UniSa. Vol.8 (jan.-mar. 2014)



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.